Ocular Therapeutix Closes $23.8M Series D Financing

Ocular Therapeutix, a Bedford, MA-based company that develops and commercializes ophthalmic therapeutic products using its proprietary hydrogel technology, recently closed a $23.8m Series D financing round.

All existing institutional investors, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures participated in the round.

The company intends to use the funds to further advance development activities and implementation of clinical trials for its sustained release drug programs, including travoprost for the treatment of glaucoma, and dexamethasone for the resolution of post-operative inflammation and pain, to support U.S. commercial launch efforts and to develop sustained release therapies for retinal diseases in collaboration with pharma partners.

Ocular, which was founded in 2006, is led by Amar Sawhney, President and CEO.



Join the discussion